Mangorx responds to and refutes recent claims made by eli lilly

Dallas, texas, oct. 21, 2024 (globe newswire) -- mangoceuticals, inc. (nasdaq: mgrx) (“mangorx” or the “company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform learned earlier this morning that eli lilly has made certain public claims alleging, and has stated that it has filed a lawsuit against mangorx claiming, that mangorx improperly copied its weight-loss medicine, zepbound and mounjaro. mangorx strongly refutes any and all claims made by eli lilly regarding the sale of compounded tirzepatide. mangorx believes it has strong arguments against eli lilly's claims and intends to vigorously defend itself in this matter.
MGRX Ratings Summary
MGRX Quant Ranking